Heart Failure and Secondary Mitral Regurgitation: Echocardiographic Outcomes from the COAPT trial Federico M. Asch, MD Director, Echocardiographic Core Lab MedStar Health Research Institute On behalf of Gregg W. Stone, Michael Mack, Neil J Weissman and the COAPT Investigators COAPT (NCT01626079)

Institutional conflict COAPT (NCT01626079) is funded by Abbott Disclosure Statement Federico M Asch, MD No personal COI Institutional conflict MedStar Health has Institutional contracts for my work as Director of an Academic Core Lab: Abbott, Boston Scientific, Edwards, Medtronic, Neovasc, Livanova, GDS, Mitralign. COAPT (NCT01626079) is funded by Abbott

Background (i) Secondary or functional mitral regurgitation (SMR) is present in >50% of patients with heart failure (HF), and is severe in ~10-15%. Prognosis is poor when SMR is severe. COAPT: Randomized, open-label, multicenter trial in patients with HF and moderate-to-severe (3+) or severe (4+) SMR who remained symptomatic despite maximally- tolerated GDMT. This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 2

Death or HF Hospitalization MitraClip + GDMT GDMT alone All-cause Mortality or HF Hospitalization (%) 0% 20% 40% 60% 80% 100% Time After Randomization (Months) 3 6 9 12 15 18 21 24 67.9% 45.7% 302 264 238 215 194 154 145 126 97 312 244 205 174 153 117 90 75 55 No. at Risk: HR [95% CI] = 0.57 [0.45-0.71] P<0.001 NNT (24 mo) = 4.5 [95% CI 3.3, 7.2] Stone GW et al. NEJM 2018;379:2307-18 This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 3

Background (ii) SMR is a consequence of leaflet tethering and incomplete leaflet coaptation. Evaluation of SMR is challenging, due to asymmetric leaflet anatomy and regurgitant orifice, eccentric jets and enlarged left cardiac chambers. Expert panels have disagreed on how to define the severity of SMR, resulting in conflicting European and American guidelines. This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 4

Objectives COAPT Echo Sub-study To describe the echocardiographic MR grading criteria utilized in COAPT for screening and post-MitraClip To describe the echocardiographic characteristics of the COAPT population To evaluate the serial echocardiographic outcomes To identify baseline echocardiographic predictors of clinical outcomes (responders and non-responders to MitraClip) This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 5

Methods 614 patients with HF and moderate to severe (3+) or severe (4+) secondary MR Randomized 1:1 to maximally-tolerated GDMT + MitraClip or GDMT alone. Transthoracic echocardiograms (TTE) at baseline, 1, 6, 12, 18, 24 months (to continue to year 5) All echo analysis by an independent echo core lab, adapted from American guidelines (ASE, ACC) This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 6

Key Echo Inclusion Criteria LVEF 20% - 50% and LVESD ≤70 mm (ischemic or non- ischemic) SMR amenable for MitraClip treatment Moderate-to-severe (3+) or severe (4+) SMR confirmed by an independent echo core laboratory prior to enrollment This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 7

Inclusion Flowchart (i) Patients with HF and MR evaluated for enrollment in COAPT N=1,576 Ineligible N=911 Inadequate MR or DMR (n=244) Echo criteria not met (n=255) Not treated with GDMT (n=79) All inclusion criteria not met (n=85) Exclusion criteria present (n=34) Incomplete screening/other (n=419) Subjects with screening TTEs and meeting all eligibility requirements for enrollment in COAPT N=665 Secondary MR, Severity 3+ or 4+ (graded by 1 of 3 criteria) Roll-in subjects N=51 Randomized subjects N=614 This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 8

Inclusion Flowchart (ii) Secondary MR, Severity 3+ or 4+ (graded by 1 of 3 criteria) Tier 1 EROA 0.2 cm2 - <0.3 cm2 With any 1 of the following: RV ≥ 45 ml/beat RF ≥ 40% VC width ≥ 0.5 cm N=70 (10.5%) Tier 2 EROA not measured or <0.2 cm2 With at least 2 of the following: RV ≥ 45 ml/beat RF ≥ 40% VC width ≥ 0.5 cm PISA radius > 0.9 cm, but CW of MR jet not done Large (≥ 6.0 cm) holosystolic jet wrapping around LA Peak E velocity ≥ 150 cm/s N=25 (3.8%) Tier 3 EROA ≥ 0.3 cm2 or PV systolic flow reversal N=570 (85.7%) MULTIPARAMETRIC ALGORITHM This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 9

Baseline Echo Characteristics (i) Device Group (N=302) Control Group (N=312) P-value LVEF, % 31.3 ± 9.1 (281) 31.3 ± 9.6 (295) 0.96 LVEDV, ml 194.4 ± 69.2 (281) 191.4 ± 73.0 (295) 0.61 LVESV, ml 135.5 ± 56.1 (281) 134.6 ± 60.4 (295) 0.85 Stroke volume, ml 50.5 ± 16.5 (283) 50.7 ± 16.9 (292) LA volume, ml 91.7 ± 36.3 (292) 91.0 ± 44.8 (303) 0.84 RVSP, mmHg 44.0 ± 13.4 (253) 44.6 ± 14.0 (275) 0.60 TR severity 0.16   - Mild (1+) 82.6% (247/299) 80.7% (242/300)   - Moderate (2+) 14.0% (42/299) 16.7% (50/300)

Baseline Echo Characteristics (ii) Device Group (N=302) Control Group (N=312) P-value MR severity, n (%) 0.13   - Moderate to severe (3+) 49.0% (148/302) 55.1% (172/312)   - Severe (4+) 51.0% (154/302) 44.9% (140/312) PISA radius, cm 0.89 ± 0.17 (293) 0.88 ± 0.18 (308) 0.62 EROA, PISA cm2 0.41 ± 0.15 (289) 0.40 ± 0.15 (303) 0.41 Reg. volume, PISA ml 59.7 ± 21.0 (288) 59.9 ± 23.5 (302) 0.91 Vena contracta, cm 0.58 ± 0.12 (277) 0.58 ± 0.12 (293) 0.88 Peak E, cm/sec 110.6 ± 28.7 (280) 109.4 ± 24.9 (286) 0.60

Baseline Echo Characteristics (iii) Device Group (N=302) Control Group (N=312) P-value Pulmonary Vein Flow   0.02   - None (0) 0.0% (0/240) 0.0% (0/234)   - Mild (1+) 0.4% (1/240) 0.9% (2/234)   - Moderate (2+) 12.9% (31/240) 12.4% (29/234)   - Moderate to severe (3+) 30.0% (72/240) 42.7% (100/234)   - Severe (4+) 56.7% (136/240) 44.0% (103/234) MR Color Flow Jet 0.18 0.0% (0/302) 0.0% (0/312) 6.0% (18/302) 6.7% (21/312) 43.0% (130/302) 47.8% (149/312) 51.0% (154/302) 45.5% (142/312)

Change in LV Volumes Over Time Left Ventricular End Diastolic Volume (LVEDV) Paired measures, follow-up minus baseline Mean ± SE * * Adjusted Change in LVEDV (mL) from Baseline Device Control * * * * 1 6 12 18 24 Months Post Procedure *p<0.05 (ANCOVA) VOLUMES INCREASED IN BOTH GROUPS BUT SIGNIFICANTLY LESS IN THE MC GROUP. ASTERISKS DENOTE SIGNIFICANT CHANGE FROM BASELINE IN EACH GROUP, NOT A COMPARISON AMONG GROUPS. Subjects with HF death prior to a follow-up visit were assigned the worst observed change from baseline at that visit. For all other subjects who had missing echo values, multiple imputation was used.

Change in LV Volumes Over Time Left Ventricular End Systolic Volume (LVESV) Paired measures, follow-up minus baseline Mean ± SE * * Adjusted Change in LVESV (mL) from Baseline Device Control Device Control * * * * * * 1 6 12 18 24 Months Post Procedure *p<0.05 (ANCOVA) MC DOES NOT CAUSE REVERSE REMODELING BUT SEMI-STABILIZE THE PROGRESSION OF THE NATURAL HISTORY IN ADVANCED CARDIOMYOPATHY Subjects with HF death prior to a follow-up visit were assigned the worst observed change from baseline at that visit. For all other subjects who had missing echo values, multiple imputation was used.

Change in Ejection Fraction Over Time Left Ventricular Ejection Fraction (LVEF) Paired measures, follow-up minus baseline Mean ± SE * * * Adjusted Change in LVEF (%) from Baseline * Device Control * * * * * 1 6 12 18 24 Months Post Procedure *p<0.05 (ANCOVA) Subjects with HF death prior to a follow-up visit were assigned the worst observed change from baseline at that visit. For all other subjects who had missing echo values, multiple imputation was used.

N denotes number of subjects with MR severity data available; Overall MR Severity Baseline 30 Days 6 Months 12 Months 18 Months 24 Months All P<0.001 MR ≤2+ Device 0.0% Control 0.0% Device 92.7% Control 34.2% Device 93.8% Control 38.1% Device 94.8% Control 46.9% Device 95.0% Control 40.4% Device 99.1% Control 43.4% 0.9% ≤1+ 2+ 3+ 4+ Percentage of Patients N=302 D=0 N=311 D=0 N=273 D=10 N=257 D=10 N=240 D=32 N=218 D=40 N=210 D=59 N=175 D=75 N=141 D=69 N=114 D=99 N=114 D=78 N=76 D=115 N denotes number of subjects with MR severity data available; D denotes subject deaths which occurred by the upper end of the visit window, whether or not the TTE was performed

MR Changes From Baseline to 12 Months Device Group (N=302) Control Group (N=312) P-value MR Severity, n (%)   <0.0001   - Improved by ≥2 grades 84.1% (243/289) 15.9% (44/277)   - Improved by 1 grade 11.1% (32/289) 40.4% (112/277)   - No change 4.8% (14/289) 36.8% (102/277)   - Worsened by 1 grade 0.0% (0/289) 6.9% (19/277) Pulmonary vein flow, n (%)   - Improved 83.6% (107/128) 39.6% (53/134) 14.8% (19/128) 40.3% (54/134)   - Worsened 1.6% (2/128) 20.1% (27/134) Vena contracta, cm -0.14 ± 0.17 (110) -0.03 ± 0.16 (186) MR color flow jet 94.1% (272/289) 54.9% (152/277) 34.3% (95/277) 1.0% (3/289) 10.8% (30/277)

Changes From Baseline to 12 Months Device Group (N=302) Control Group (N=312) P-value TR severity, n (%)   0.34   - Improved 10.6% (30/282) 13.4% (35/261)   - No change 71.6% (202/282) 70.5% (184/261)   - Worsened 17.7% (50/282) 16.1% (42/261) RVSP, mmHg -3.5 ± 14.3 (202) -2.1 ± 14.7 (211) 0.13

24-Month All-cause Mortality or First HF Hospitalization (i) Subgroup MitraClip + GDMT GDMT Alone HR [95% CI] P [Int] All patients 45.4% (128) 67.4% (189) 0.57 [0.45, 0.71] Baseline LVEF ≥ 30% (median: n=301) 44.1% (62) 60.5% (84) 0.61 [0.44, 0.85] 0.29 < 30% (median: n=274) 45.8% (55) 77.6% (98) 0.46 [0.33, 0.64] > 40% (n=103) 49.7% (22) 53.5% (26) 0.70 [0.39, 1.23] 0.26 ≤ 40% (n=472) 43.8% (95) 71.8% (156) 0.50 [0.39, 0.65] LVEDV (median) ≥ 181 mL (n=288) 48.3% (63) 68.0% (92) 0.57 [0.41, 0.79] 0.52 < 181 mL (n=287) 41.5% (54) 68.5% (90) 0.49 [0.35, 0.69] LVESV (median) ≥ 124 mL (n=288) 46.8% (60) 71.1% (97) 0.51 [0.37, 0.71] 0.83 < 124 mL (n=287) 43.1% (57) 65.7% (85) 0.55 [0.39, 0.77] LV Stroke Volume (median) ≥ 49 mL (n=286) 46.0% (60) 65.0% (88) 0.64 [0.46, 0.89] 0.30 < 49 mL (n=289) 44.3% (59) 69.5% (89) LVEDD (median) ≥ 6.1 cm (n=340) 48.4% (76) 71.2% (110) 0.56 [0.41, 0.75] 0.94 < 6.1 cm (n=268) 41.9% (52) 64.3% (79) 0.56 [0.39, 0.79] 0.2 0.5 1 1.5 2.5 Favors MitraClip + GDMT Favors GDMT alone

24-Month All-cause Mortality or First HF Hospitalization (ii) Subgroup MitraClip + GDMT GDMT Alone HR [95% CI] P [Int] All patients 45.4% (128) 67.4% (189) 0.57 [0.45, 0.71] MR Severity 3+ (n=320) 36.9% (50) 64.4% (98) 0.48 [0.34, 0.68] 0.30 4+ (n=293) 53.4% (78) 71.4% (91) 0.62 [0.45, 0.83] PISA Radius (median) ≥ 0.87 cm (n=306) 48.2% (72) 66.5% (92) 0.57 [0.42, 0.78] 0.86 < 0.87 cm (n=294) 42.0% (52) 67.1% (94) 0.54 [0.39, 0.76] EROA, PISA (median) ≥ 0.37 cm2 (n=309) 49.8% (75) 73.7% (102) 0.52 [0.38, 0.70] 0.91 < 0.37 cm2 (n=282) 37.9% (45) 60.4% (81) 0.54 [0.37, 0.78] Reg Vol, PISA (median) ≥ 23 mL (n=138) 45.1% (30) 62.2% (38) 0.50 [0.31, 0.81] 0.71 < 23 mL (n=122) 40.1% (19) 73.5% (47) 0.43 [0.25, 0.74] Reg Fraction (median) ≥ 36% (n=135) 45.7% (28) 70.5% (43) 0.44 [0.27, 0.71] 0.75 < 36% (n=124) 40.9% (21 67.1% (42) 0.50 [0.29, 0.85] 0.2 0.5 1 1.5 2.5 Favors MitraClip + GDMT Favors GDMT alone

24-Month All-cause Mortality or First HF Hospitalization (iii) Subgroup MitraClip + GDMT GDMT Alone HR [95% CI] P [Int] Vena Contracta (median) ≥ 0.57 cm (n=294) 46.8% (65) 69.3% (93) 0.53 [0.38, 0.73] 0.62 < 0.57 cm (n=275) 44.4% (54) 66.4% (86) 0.59 [0.42, 0.83] Pulmonary Vein Flow 0 / 1+ / 2+ (n=63) 34.8% (10) 62.7% (19) 0.41 [0.19, 0.89] 0.28 3+ (n=172) 42.1% (28) 72.5% (64) 0.43 [0.28, 0.68] 4+ (n=238) 49.5% (63) 66.5% (61) 0.65 [0.46, 0.92] TR severity ≤ 1+ (n=501) 44.7% (107) 64.5% (143) 0.61 [0.47, 0.78] 0.21 ≥ 2+ (n=98) 49.9% (20) 81.0% (40) 0.43 [0.25, 0.74] Peak E (median) ≥ 109 cm/sec (n=292) 49.7% (68) 73.7% (98) 0.52 [0.38, 0.72] 0.25 < 109 cm/sec (n=274) 41.8% (52) 58.5% (73) 0.69 [0.48, 0.99] RVSP (median) ≥ 43 mmHg (n=276) 55.8% (69) 76.8% (103) 0.62 [0.45, 0.84] 0.79 < 43 mmHg (n=252) 36.1% (40) 53.9% (61) 0.58 [0.39, 0.86] Tier of Echo Eligibility Tier 1 (n=530) 47.2% (117) 67.0% (161) 0.58 [0.46, 0.74] Tier 2 (n=61) 17.4% (4) 67.9% (23) 0.23 [0.08, 0.68] Tier 3 (n=23) 50.0% (7) 70.0% (5) 0.80 [0.25, 2.54] 0.2 0.5 1 1.5 2.5 Favors MitraClip + GDMT Favors GDMT alone

Predictors of 24-Month Mortality or First HF Hospitalization Multivariable Cox regression MitraClip + GDMT GDMT Alone   Hazard Ratio [95% CI] P-Value   RVSP (mmHg) 1.02 [1.01, 1.04] 0.005   STS Repl Score 1.12 [1.02, 1.23] 0.020   LVEDV (mL) 1.00 [1.00, 1.01] 0.07 Sex (Female vs Male) 0.64 [0.37, 1.08] 0.09 EROA, PISA (cm2) 2.56 [0.79, 8.26] 0.12   Isch vs Non-Isch CM 0.70 [0.43, 1.13] 0.15   STS Repair Score 0.95 [0.88, 1.04] 0.26   LVEF (%) 1.01 [0.98, 1.03] 0.56   Age (years) 0.57   TR Grade (≥2+ vs ≤1+) 0.90 [0.51, 1.61] 0.73   Hazard Ratio [95% CI] P-Value   TR Grade (≥ 2+ vs ≤ 1+) 1.60 [1.07, 2.39] 0.022   LVEF (%) 0.98 [0.96, 1.00] 0.027 RVSP (mmHg) 1.01 [1.00, 1.02] 0.032   EROA, PISA (cm2) 3.15 [1.08, 9.21] 0.036   STS Repl Score 1.07 [0.98, 1.18] 0.14   Age (years) 0.99 [0.97, 1.01] 0.24 STS Repair Score 0.96 [0.87, 1.07] 0.47   Isch vs Non-Isch CM 0.92 [0.62, 1.36] 0.66   LVEDV (mL) 1.00 [1.00, 1.00] 0.84   Sex (Female vs Male) 0.97 [0.64, 1.46] 0.87

Limitations Echo analysis was blinded to clinical condition, but not to intervention. PISA and hemodynamics after MitraClip have major limitations. Color Doppler, PV flow and vena contracta are the most available and reliable methods. Subgroup predictive analysis was only done based on pre- specified plans. To overcome survivorship bias, worst case scenario and multiple imputation methods were used to account for missing follow-up data (pre-specified).

Conclusions (i) COAPT Echo Sub-study To duplicate the COAPT results, specific COAPT screening echo criteria and expert echo analysis should be applied to identify proper candidates for MitraClip. In patients with HF and 3+ or 4+ secondary MR, TMVr with MitraClip provided substantial death and HFH benefits in all echocardiographic subgroups, regardless of degree of LV dysfunction, LV dimensions, pulmonary hypertension, severity of TR or individual MR parameters (all responders). This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 24

Conclusions (ii) COAPT Echo Sub-study Baseline LVEF, TR and MR severity predicted poor outcomes in patients with HF treated with GDMT alone, but not after MR was corrected by MitraClip. RVSP was the only independent echocardiographic predictor of poor outcomes after MitraClip and GDMT treatments. This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 25

Acknowledgments COAPT Principal Investigators and Co-authors Gregg W. Stone, Michael J. Mack, William T. Abraham, JoAnn Lindenfeld, Paul A. Grayburn, Robert J. Siegel, Saibal Kar, D. Scott Lim, Jonathan G. Zaroff, Jacob M. Mishell, Brian Whisenant and Neil J. Weissman Abbott Structural Heart Global Clinical Affairs Jeffrey Ellis, Kartik Sundareswaran Abbott Global Biometrics Yu Shu, Juanjuan Li, Deepika Morishetti, Hong Nie All COAPT Sites, Research Coordinators, Heart Teams and Patients MedStar Echo Core lab Staff Vladimir Masati, Valiere Morgan, Ma Therese Tupas-Habib, et al. This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 26